A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

This trial is testing a new treatment called INT2104 — a type of immune cell therapy — for people with B-cell lymphomas (cancers of certain white blood cells) that have come back after multiple previous treatments. The study is looking at whether INT2104 is safe and at what dose. **You may be eligible if...** - You are 18 or older with a type of B-cell lymphoma (such as diffuse large B-cell lymphoma or other B-NHL subtypes) that has relapsed or not responded to at least 2 prior treatments - Your tumor tests positive for a protein called CD20 - You have measurable disease visible on scans - You have not had more than one prior CAR-T cell therapy **You may NOT be eligible if...** - Your cancer does not have CD20 on the tumor cells - You have had more than one prior CAR-T or other genetically modified T-cell therapy - You are pregnant or unable to use effective contraception Talk to your doctor to see if this trial is right for you.